SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease.

作者信息

Tuttle Katherine R

机构信息

Providence Medical Research Center, Providence Health Care, Nephrology Division, Kidney Research Institute, and Institute of Translational Health Sciences, University of Washington, Spokane, WA 99204, USA.

出版信息

Lancet Diabetes Endocrinol. 2019 Jun;7(6):414-415. doi: 10.1016/S2213-8587(19)30116-0. Epub 2019 Apr 13.

DOI:10.1016/S2213-8587(19)30116-0

PMID:30992196

Abstract

摘要

相似文献

SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease.

Lancet Diabetes Endocrinol. 2019 Jun;7(6):414-415. doi: 10.1016/S2213-8587(19)30116-0. Epub 2019 Apr 13.

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.达格列净单药及联合沙格列汀降低蛋白尿的效果及在 2 型糖尿病合并慢性肾脏病患者中的血糖控制效果（DELIGHT）：一项随机、双盲、安慰剂对照试验。

Lancet Diabetes Endocrinol. 2019 Jun;7(6):429-441. doi: 10.1016/S2213-8587(19)30086-5. Epub 2019 Apr 13.

Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?钠-葡萄糖协同转运蛋白2抑制剂降低蛋白尿：无糖尿病患者肾脏结局改善的标志物？

Lancet Diabetes Endocrinol. 2020 Jul;8(7):553-555. doi: 10.1016/S2213-8587(20)30185-6.

Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.联合 SGLT2 和 DPP4 抑制可减少 2 型糖尿病小鼠 NLRP3/ASC 炎性小体的激活并减轻糖尿病肾病的发展。

Cardiovasc Drugs Ther. 2018 Apr;32(2):135-145. doi: 10.1007/s10557-018-6778-x.

Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂联合二肽基肽酶-4（DPP-4）抑制剂的联合疗法在2型糖尿病管理中处于什么地位？

Diabetes Care. 2015 Mar;38(3):373-5. doi: 10.2337/dc14-2517.

Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?达格列净抑制 SGLT2 是否克服了 RAAS 抑制的个体治疗抵抗？

Diabetes Obes Metab. 2018 Jan;20(1):224-227. doi: 10.1111/dom.13057. Epub 2017 Aug 8.

Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.达格列净和沙格列汀片用于成人2型糖尿病患者。

Expert Rev Clin Pharmacol. 2017 Dec;10(12):1303-1316. doi: 10.1080/17512433.2017.1389645. Epub 2017 Oct 18.

SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.达格列净抑制SGLT-2可降低Nlrp3/ASC炎性小体的激活，并减轻2型糖尿病小鼠糖尿病性心肌病的发展。二肽基肽酶4抑制剂沙格列汀可进一步增强其作用效果。

Cardiovasc Drugs Ther. 2017 Apr;31(2):119-132. doi: 10.1007/s10557-017-6725-2.

Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.达格列净/沙格列汀（Qtern）用于2型糖尿病。

Med Lett Drugs Ther. 2018 Mar 26;60(1543):55-56.

Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?

Can J Diabetes. 2017 Feb;41(1):6-9. doi: 10.1016/j.jcjd.2016.08.001. Epub 2016 Nov 10.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验